Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jun 12;121(2):125–130. doi: 10.1038/s41416-019-0491-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Cancer Research UK 2019

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

PMC Copyright notice

Fig. 3 — Treatment allocation based on cfDNA concentration (a) and RMH score (b). The percentage of patients allocated to further treatment or not are indicated based on either cfDNA quantiles (25 percentile: 7.4 ng/ml; 50 percentiles: 17.1 ng/ml; 75 percentiles: 39.55 ng/ml) or RMH score (0–3). Treatment allocation included treatments in a non-phase 1 setting (“Other”), off-label treatment with approved therapy in other diagnosis (“Off-label”) and patients in a phase 1 protocol treatment (“Protocol”). N indicates the number of patients in each group. Note that patients are equally distributed in cfDNA quantiles (a) in contrast to RMH score (b)